Price (90d)
$215.77Signal Score (90d)
53Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $638.50M | $-183.17M | $-3.68 |
| 2024 | $385.69M | $-287.22M | $-5.99 |
| 2023 | $270.60M | $-239.24M | $-5.27 |
| 2022 | $50.04M | $-187.13M | $-4.60 |
| 2021 | $0.00 | $-130.40M | $-3.47 |
Social Signal Score
Earnings
Mon, Nov 2(in 3 months)
Consensus estimate $-0.49 per share
Typical surprise -1.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.99 vs $-0.89miss
- Mon, May 4$-1.26 vs $-0.85miss
- Mon, Feb 23$-0.71 vs $-0.70miss
- Mon, Nov 3$-0.94 vs $-0.82miss
- Mon, Aug 4$-0.92 vs $-1.00beat
- Mon, May 5$-0.80 vs $-1.26beat
Estimates and results for AXSM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
AXSMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (7)
- Newszacks.com·3d ago·Negative
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt
View source ↗ - News (Marketaux)seekingalpha.com·4d ago·Neutral
Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-08-11 Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-08-11
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·5d ago·Neutral
Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·5d ago·Negative
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.
View source ↗ - Newsmarketbeat.com·5d ago·Positive
Axsome Therapeutics Q2 Earnings Call Highlights Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.
View source ↗